Background Dual antiplatelet therapy with aspirin and an oral P2Y 12 receptor inhibitor is the standard care to prevent the short and long term risk of recurrent athero-thrombotic events in high risk settings.Given that the risk of bleeding is significantly increased among patients undergoing surgical procedures,in particular cardiac surgery,guidelines suggested the discontinuation of antiplatelet therapy about 5 to 7 days that allows recovery of platelet function is warranted.The purpose of this study was to evaluate the use of sarpogrelate,an oral,reversible 5-HT2 platelet inhibitor for patients bridging dual-antiplatelet treatment to coronary artery bypass grafting (CABG).